Similar Articles |
|
The Motley Fool January 30, 2007 Ryan Fuhrmann |
Zimmer Implants a New High Investors, the orthopedic designer, developer, and manufacturer isn't cheap, but stellar companies rarely are. |
The Motley Fool March 22, 2005 Stephen D. Simpson |
Can Biomet Elbow the Competition? The No. 4 player in orthopedics looks to close the gap. No matter what valuation metric you want to look at, Biomet shares look expensive on an absolute basis. |
The Motley Fool June 30, 2005 Stephen D. Simpson |
Biomet Wants Your Body Steady growth continues at the #4 orthopedics player. But Biomet shares haven't had a great year so far, hovering close to their 52-week low. |
The Motley Fool July 26, 2007 Ryan Fuhrmann |
Zimmer Simmers The maker of hip and knee replacements gets a leg up on the market. Investors, take note. |
The Motley Fool April 27, 2007 Ryan Fuhrmann |
Hip Results at Zimmer Holdings The orthopedic-implant and surgical-product maker is impressing investors, and it may just be warming up. |
The Motley Fool February 1, 2005 Stephen D. Simpson |
Zimmer Shoots From the Hip Pure-play orthopedic company delivers the goods, but at what cost? Zimmer carries a price tag that would make a value investor's bones ache. |
The Motley Fool October 27, 2005 Stephen D. Simpson |
Will Smith & Nephew Keep Flexing? This smaller, British, orthopedic company has competitive products, but industry trends could hurt it. However, the entire orthopedic sector is getting pretty interesting from a value perspective. |
The Motley Fool January 31, 2006 Stephen D. Simpson |
Zimmer Muddles Through So long as the pressures in the orthopedic sector prove less than originally feared, investors could still make money here. |
The Motley Fool April 27, 2006 Stephen D. Simpson |
Guidance Brings Zimmer to Its Knees Sales were a little light this quarter, and the company will have to hustle to meet full-year projections. Investors, tread carefully and only buy when there is a fitting margin of safety here. |
The Motley Fool July 23, 2010 Jordan DiPietro |
Better Health Care Buy: Stryker or Zimmer Holdings? Which stock is a better purchase to consider? |
The Motley Fool July 27, 2006 Stephen D. Simpson |
Smith & Nephew: Better Is Good Enough For British medical device company Smith & Nephew investors, better-than-expected is just fine. |
The Motley Fool November 6, 2006 Matthew Crews |
Smith & Nephew Is Hip to Growth The medical technology company is showing solid growth, but a possible acquisition is cause for concern. Investors, take note. |
The Motley Fool September 21, 2005 Stephen D. Simpson |
Can Biomet Stay Limber? Concerns about pricing have buffeted the orthopedic space and the No. 4 player in hips and knees. Whatever the case turns out to be, Biomet is probably a bit riskier than average. |
The Motley Fool December 21, 2005 Stephen D. Simpson |
Biomet Takes a Bum Knee Company excuses aside, a subpar quarter lends credence to the notion that orthopedics companies are still in a tough spot. Investors, take note. |
The Motley Fool April 13, 2006 Stephen D. Simpson |
A Foolish Baby Shower: Stryker Here is a stock you can be comfortable with buying for your little one with the intention that it would be held for at least 18 years. |
The Motley Fool April 21, 2006 Stephen D. Simpson |
Stryker Strikes a Chord A solid quarter and generally positive guidance refuels investor enthusiasm. |
The Motley Fool October 17, 2008 Brian Orelli |
Shareholders Slap Stryker A little earnings miss sends the medical technology company down more than necessary. |
The Motley Fool December 12, 2006 Matthew Crews |
Smith & Nephew, What's the Deal? A merger with Biomet would be good in many ways. But what's the right price? Investors, take note. |
BusinessWeek November 12, 2007 Arlene Weintraub |
Getting Hip to the Boomers Stryker's new orthopedic technology gives aging patients an alternative to full joint replacement. |
The Motley Fool January 28, 2011 Michael Olsen |
Rising Star Buy: Zimmer Holdings Current trends, coupled with an aging population, should provide consistent and growing demand for Zimmer's wares. |
The Motley Fool April 28, 2004 Glen Trematore |
Zimmer Makes a Family Proud Zimmer Holdings looks strong when compared with other orthopedic/medical device makers. |
The Motley Fool September 25, 2006 Anders Bylund |
3 Stocks That Missed the Mark A peek at companies that over-promised and under-delivered: Biomet... A.G. Edwards... 3Com... |
The Motley Fool February 9, 2006 Stephen D. Simpson |
Growth Not Enough for Smith & Nephew This orthopedic company has market-leading growth, but just not enough cash flow. Investors shouldn't get too excited about these shares. |
The Motley Fool March 31, 2005 Stephen D. Simpson |
The DOJ Goes Fishing for Orthopedics The government's industry-wide investigation of orthopedics is more of a buying opportunity than a real threat. |
The Motley Fool August 28, 2008 Brian Orelli |
Stryker Strikes Back The orthopedics maker sues to stop a costly federal investigation. |
The Motley Fool March 20, 2006 Rich Smith |
Foolish Forecast: Biomet Flexes The bone specialist is due to release its fiscal third-quarter 2006 report tomorrow morning. Here's what investors need to know to make sense of it. |
The Motley Fool July 18, 2008 Brian Orelli |
What Strikes Against Stryker? High growth isn't enough to impress investors. |
The Motley Fool January 29, 2007 Matthew Crews |
Only One Bone to Pick With Stryker With products for wherever you hurt, the med-tech company continues to deliver solid earnings. |
The Motley Fool October 5, 2005 Stephen D. Simpson |
Wright Goes Wrong A weak third quarter compounds troubles for this pipeline-challenged orthopedics player. There is no compelling reason to purchase this stock today. |
The Motley Fool October 19, 2005 Stephen D. Simpson |
Stryker Still on Target The ever-present 20% growth target will get tougher to hit, but this is a quality medical company. Investors, take note. |
The Motley Fool July 23, 2009 Robert Steyer |
Long Convalescence for Device Makers Orthopedic product specialists Stryker and Zimmer Holdings forecast a slow-motion recovery. |
The Motley Fool July 28, 2005 Stephen D. Simpson |
Zimmer at a Simmer Strong demand for reconstructive products keeps this orthopedics company limber. Zimmer's 30-plus trailing price-to-earnings ratio still looks high, but it is in line with this industry's current multiples. |
The Motley Fool January 27, 2006 Stephen D. Simpson |
Lightning Stryker The dust hasn't yet settled on the orthopedic sector, so wise investors should tread lightly with this medical technology company. |
The Motley Fool March 9, 2004 Rich Smith |
Interpore Gets Transplanted Will its acquisition by medical equipment maker Biomet pay off for Interpore's shareholders? |
The Motley Fool March 21, 2006 Stephen D. Simpson |
Biomet's Stiff Joints Pricing isn't collapsing, but the orthopedics company isn't exactly prospering, either. Investors, beware. |
The Motley Fool October 18, 2007 Billy Fisher |
An Empire Strykes Back Stryker reports a quarter of double-digit growth in revenue and earnings. Investors, take note. |
The Motley Fool April 16, 2004 Bill Mann |
Stryker Hits It Again Stryker, the medical device company, reported year-over-year gains in revenues of 22%, with sales just over $1 billion. Earnings were even better: Stryker topped off last year's results by more than 30%. |
The Motley Fool April 26, 2007 Ryan Fuhrmann |
Zimmer Holding Steady: Fool by Numbers The orthopedic designer, developer, and manufacturer released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool October 25, 2007 Billy Fisher |
Plenty of Strength in Zimmer Orthopedic manufacturer Zimmer Holdings reports a solid third quarter, but lowers its forecast for Q4. |
The Motley Fool September 14, 2005 Stephen D. Simpson |
Orthopedic Sector Stumbles Already antsy about potential pricing, investors reacted badly to British orthopedic company Smith & Nephew's earnings guidance. |
The Motley Fool June 28, 2006 Stephen D. Simpson |
Feds Once Again Knocking on Ortho Doors A second round of subpoenas rattles the medical device sector. |
The Motley Fool July 20, 2007 Ryan Fuhrmann |
Stryker Does a Body Good The orthopedics company continues its double-digit growth in an industry with a bright future. Investors, take note. |
The Motley Fool July 21, 2006 Stephen D. Simpson |
Stryker and the Terror of the Unknown This has been a pretty bad year to be a good medical technology company. Fears about future pricing and the DOJ investigation keep a lid on the entire sector. So, what about that future for Stryker? Investors, take note. |
BusinessWeek December 3, 2007 Arlene Weintraub |
Is the Hip Bone Connected To a Fee? An investigation alleges some orthopedics makers have showered surgeons with fees and perks. |
The Motley Fool June 24, 2005 Rick Aristotle Munarriz |
The Fool's Look Ahead Monday: Nike's top line should continue to move higher... Tuesday: For years, investors in Apollo Group have been schooling the market... Wednesday: Even if you don't own shares of software giant Oracle, you should still tune in for its midweek earnings report... etc. |
The Motley Fool September 5, 2008 Brian Orelli |
Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business. |
The Motley Fool March 28, 2006 Stephen D. Simpson |
A Surprising Turn at Biomet The large orthopedic company replaces one of its founders. This change doesn't really make the stock dramatically more, or less, attractive than before. Investors, take note. |
The Motley Fool May 17, 2006 S.J. Caplan |
A Shapelier Knee Zimmer gains clearance for a female knee-replacement device. The company's new device should certainly be able to boost revenue by being first to exploit the female marketing angle. Investors, take note. |
The Motley Fool January 28, 2009 Brian Orelli |
The Streak Is Over After 31 consecutive quarters of double-digit sales growth, medical device maker Stryker finally had an off quarter. |
The Motley Fool July 27, 2006 Stephen D. Simpson |
Zimmer Provides Quarterly Information, and More In addition to its quarterly review, the orthopedic company gave some insight into the government probe. Investors, take note. |